Natera (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 1,906 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Brophy sold 1,906 shares of Natera stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $425.55, for a total transaction of $811,098.30. Following the sale, the chief financial officer owned 46,574 shares in the company, valued at $19,819,565.70. This represents a 3.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, October 28th, Michael Brophy sold 1,198 shares of Natera stock. The shares were sold at an average price of $426.34, for a total transaction of $510,755.32.
• On Tuesday, October 27th, Michael Brophy sold 781 shares of Natera stock. The shares were sold at an average price of $406.00, for a total transaction of $317,086.00.
• On Tuesday, August 4th, Michael Brophy sold 478 shares of Natera stock. The stock was sold at an average price of $274.22, for a total transaction of $131,077.16.
• On Monday, August 3rd, Michael Brophy sold 317 shares of Natera stock. The stock was sold at an average price of $267.99, for a total transaction of $84,952.83.

Natera Stock Performance

Shares of Natera stock opened at $414.30 on Friday. Natera, Inc. has a 1-year low of $181.00 and a 1-year high of $437.41. The business has a 50-day moving average of $377.06 and a 200-day moving average of $266.44.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The firm had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. During the same quarter in the prior year, the business posted ($0.74) earnings per share. Natera’s revenue for the quarter was up 37.7% on a year-over-year basis. As a group, analysts predict that Natera, Inc. will post -1.14 EPS for the current fiscal year.

Analysts Set New Price Targets

NTRA has been the subject of a number of research analyst reports. Citigroup lifted their price target on shares of Natera from $365.00 to $480.00 and gave the stock a “buy” rating in a research note on Tuesday, October 6th. Canaccord Genuity Group increased their price objective on shares of Natera from $375.00 to $500.00 and gave the company a “buy” rating in a research note on Monday, October 19th. BTIG Research increased their price objective on shares of Natera from $320.00 to $430.00 and gave the company a “buy” rating in a research note on Tuesday. Royal Bank Of Canada raised their price objective on shares of Natera from $350.00 to $460.00 and gave the stock an “outperform” rating in a report on Friday, September 25th. Finally, Evercore reissued an “outperform” rating and issued a $300.00 target price on shares of Natera in a research report on Monday, July 6th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $394.31.

Key Stories Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera’s stock momentum remains strong after reaching a new 52-week high of approximately $436, reflecting continued investor enthusiasm for its oncology testing business and Signatera growth prospects. Natera reaches a fresh 52-week high
• Positive Sentiment: Recent ESMO oncology data, including 25 company presentations and additional Signatera evidence, could support broader clinical adoption and future revenue growth. Natera presents 25 ESMO abstracts
• Neutral Sentiment: Natera is scheduled to report third-quarter 2026 results after the market closes on November 5. The report will provide a near-term catalyst focused on Signatera testing volumes, pricing, reimbursement and profitability. Natera third-quarter results announcement
• Negative Sentiment: Several insiders sold shares this week, including the CEO, CFO and other executives. The transactions totaled roughly 11,500 shares, but each sale was made under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards, making the signal less concerning than discretionary selling. Natera insider selling
• Negative Sentiment: Zacks warned that Natera may report another quarterly loss and does not currently show the usual combination of positive estimate revisions and earnings momentum associated with a likely beat. With the stock trading well above its long-term moving averages and some valuation analyses estimating substantial downside to fair value, investors may be taking profits ahead of earnings. Natera earnings outlook

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Trust Co. of Vermont bought a new position in shares of Natera in the second quarter valued at $26,000. Elevation Wealth Partners LLC acquired a new stake in shares of Natera during the 2nd quarter valued at $30,000. Continuum Advisory LLC acquired a new stake in shares of Natera during the 2nd quarter valued at $33,000. International Assets Investment Management LLC lifted its position in shares of Natera by 132.9% during the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 97 shares during the last quarter. Finally, Rakuten Securities Inc. bought a new stake in shares of Natera during the 2nd quarter worth $35,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.